New drug cocktail targets metastatic colorectal cancer in early trial
NCT ID NCT06696768
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 38 times
Summary
This early-phase trial is testing whether adding an experimental drug called CA-4948 to standard chemotherapy (FOLFOX) and a targeted therapy (bevacizumab) is safe for people with metastatic colorectal cancer. About 24 adults whose cancer has spread and cannot be surgically removed will take part. The main goals are to find the best dose and identify any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Hospital East
RECRUITINGShiloh, Illinois, 62269, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center at Christian Hospital
RECRUITINGSt Louis, Missouri, 63136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center at Saint Peters Hospital
RECRUITINGCity of Saint Peters, Missouri, 63376, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center at West County Hospital
RECRUITINGCreve Coeur, Missouri, 63141, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center-South County
RECRUITINGSt Louis, Missouri, 63129, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UF Health Cancer Institute - Gainesville
RECRUITINGGainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Kansas Cancer Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Clinical Research Center
RECRUITINGFairway, Kansas, 66205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Hospital-Indian Creek Campus
RECRUITINGOverland Park, Kansas, 66211, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Hospital-Westwood Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CA-4948 (emavusertib) combined with FOLFOX (fluorouracil, leucovorin, oxaliplatin) and bevacizumab
What this could lead to
If this combination proves safe and effective, it could offer a new frontline treatment option for people with metastatic colorectal cancer.
What could go wrong
This is a very early Phase I trial with only 24 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug combination may cause significant side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.